Documento completo  |  Capítulo completo  |  Expandir índice  |  Versión HTML imprimible
WHO Basic Training Modules on Good Manufacturing Practices (GMP) - Basic Principles of GMP: Module 1 (Part 15): Active Pharmaceutical Ingredients
(2006; 23 pages)
Índice de contenido
Ver el documentoBasic Principles of GMP
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
Ver el documentoActive Pharmaceutical Ingredients
 

Active Pharmaceutical Ingredients

Possible Issues

  • Manufacturers supplying various types of industries

  • Imports through brokers

  • Hazardous processes

  • Commercial secrecy

  • Unsatisfactory final facilities

Possible situations that might be experienced include:

  • Manufacturers that are not prepared to provide the standards needed for pharmaceuticals.

  • Manufacturers may not be interested in supplying the pharmaceutical industry.

  • Manufacturers who refuse to accept inspections.

Sometimes the only route to obtain supplies is through the use of brokers. They may be unwilling or unable to identify their suppliers. They may not use the same supplier on a regular basis.

It may be that the process is so hazardous that inspection during manufacturing is not possible.

A company may state that it will not permit an inspection because of commercial secrecy about the process.

A frequent situation is that the final processing conditions do not match those required for the processing of the finished pharmaceutical form. The company refuses to make the investment needed.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 7 octubre 2014